REGENXBIO (RGNX) Competitors

REGENXBIO logo
$7.24 -0.08 (-1.09%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$7.48 +0.25 (+3.38%)
As of 11/17/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

RGNX vs. REPL, TRAX, VCYT, COAG, and RXRX

Should you buy REGENXBIO stock or one of its competitors? REGENXBIO's main competitors and comparable companies include Replimune Group (REPL), First Tracks Biotherapeutics (TRAX), Veracyte (VCYT), Hemab Therapeutics (COAG), and Recursion Pharmaceuticals (RXRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does REGENXBIO compare to Replimune Group?

Replimune Group (NASDAQ:REPL) and REGENXBIO (NASDAQ:RGNX) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations and profitability.

Replimune Group has a beta of 0.93, meaning that its share price is 7% less volatile than the broader market. Comparatively, REGENXBIO has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market.

Replimune Group has a net margin of 0.00% compared to REGENXBIO's net margin of -113.85%. Replimune Group's return on equity of -157.78% beat REGENXBIO's return on equity.

Company Net Margins Return on Equity Return on Assets
Replimune GroupN/A -157.78% -83.89%
REGENXBIO -113.85%-203.98%-42.54%

In the previous week, Replimune Group had 3 more articles in the media than REGENXBIO. MarketBeat recorded 8 mentions for Replimune Group and 5 mentions for REGENXBIO. Replimune Group's average media sentiment score of 0.50 beat REGENXBIO's score of 0.02 indicating that Replimune Group is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Replimune Group
1 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
REGENXBIO
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Replimune Group presently has a consensus price target of $18.17, suggesting a potential downside of 7.74%. REGENXBIO has a consensus price target of $23.18, suggesting a potential upside of 220.19%. Given REGENXBIO's stronger consensus rating and higher probable upside, analysts plainly believe REGENXBIO is more favorable than Replimune Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Replimune Group
2 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.50
REGENXBIO
1 Sell rating(s)
3 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.69

REGENXBIO has higher revenue and earnings than Replimune Group. Replimune Group is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Replimune GroupN/AN/A-$313.94M-$2.79N/A
REGENXBIO$170.44M2.81-$193.88M-$3.21N/A

92.5% of Replimune Group shares are held by institutional investors. Comparatively, 88.1% of REGENXBIO shares are held by institutional investors. 5.4% of Replimune Group shares are held by company insiders. Comparatively, 14.2% of REGENXBIO shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

REGENXBIO beats Replimune Group on 9 of the 15 factors compared between the two stocks.

How does REGENXBIO compare to First Tracks Biotherapeutics?

First Tracks Biotherapeutics (NASDAQ:TRAX) and REGENXBIO (NASDAQ:RGNX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

First Tracks Biotherapeutics has higher earnings, but lower revenue than REGENXBIO. First Tracks Biotherapeutics is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
First Tracks BiotherapeuticsN/AN/AN/A-$2.79N/A
REGENXBIO$170.44M2.81-$193.88M-$3.21N/A

88.1% of REGENXBIO shares are held by institutional investors. 14.2% of REGENXBIO shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

First Tracks Biotherapeutics currently has a consensus target price of $72.17, suggesting a potential upside of 65.63%. REGENXBIO has a consensus target price of $23.18, suggesting a potential upside of 220.19%. Given REGENXBIO's higher probable upside, analysts plainly believe REGENXBIO is more favorable than First Tracks Biotherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
First Tracks Biotherapeutics
1 Sell rating(s)
1 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.79
REGENXBIO
1 Sell rating(s)
3 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.69

First Tracks Biotherapeutics has a net margin of 0.00% compared to REGENXBIO's net margin of -113.85%. First Tracks Biotherapeutics' return on equity of 0.00% beat REGENXBIO's return on equity.

Company Net Margins Return on Equity Return on Assets
First Tracks BiotherapeuticsN/A N/A N/A
REGENXBIO -113.85%-203.98%-42.54%

In the previous week, REGENXBIO had 4 more articles in the media than First Tracks Biotherapeutics. MarketBeat recorded 5 mentions for REGENXBIO and 1 mentions for First Tracks Biotherapeutics. First Tracks Biotherapeutics' average media sentiment score of 1.46 beat REGENXBIO's score of 0.02 indicating that First Tracks Biotherapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
First Tracks Biotherapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
REGENXBIO
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

First Tracks Biotherapeutics beats REGENXBIO on 7 of the 13 factors compared between the two stocks.

How does REGENXBIO compare to Veracyte?

Veracyte (NASDAQ:VCYT) and REGENXBIO (NASDAQ:RGNX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, media sentiment, profitability, dividends, valuation and institutional ownership.

Veracyte presently has a consensus target price of $44.50, indicating a potential upside of 83.66%. REGENXBIO has a consensus target price of $23.18, indicating a potential upside of 220.19%. Given REGENXBIO's stronger consensus rating and higher probable upside, analysts clearly believe REGENXBIO is more favorable than Veracyte.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Veracyte
1 Sell rating(s)
5 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.42
REGENXBIO
1 Sell rating(s)
3 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.69

Veracyte has higher revenue and earnings than REGENXBIO. REGENXBIO is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Veracyte$517.15M3.78$66.35M$1.5515.63
REGENXBIO$170.44M2.81-$193.88M-$3.21N/A

In the previous week, Veracyte had 3 more articles in the media than REGENXBIO. MarketBeat recorded 8 mentions for Veracyte and 5 mentions for REGENXBIO. Veracyte's average media sentiment score of 0.12 beat REGENXBIO's score of 0.02 indicating that Veracyte is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Veracyte
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
REGENXBIO
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Veracyte has a net margin of 21.80% compared to REGENXBIO's net margin of -113.85%. Veracyte's return on equity of 8.99% beat REGENXBIO's return on equity.

Company Net Margins Return on Equity Return on Assets
Veracyte21.80% 8.99% 8.34%
REGENXBIO -113.85%-203.98%-42.54%

Veracyte has a beta of 1.98, meaning that its stock price is 98% more volatile than the broader market. Comparatively, REGENXBIO has a beta of 1.24, meaning that its stock price is 24% more volatile than the broader market.

88.1% of REGENXBIO shares are owned by institutional investors. 1.6% of Veracyte shares are owned by insiders. Comparatively, 14.2% of REGENXBIO shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Veracyte beats REGENXBIO on 11 of the 17 factors compared between the two stocks.

How does REGENXBIO compare to Hemab Therapeutics?

REGENXBIO (NASDAQ:RGNX) and Hemab Therapeutics (NASDAQ:COAG) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, analyst recommendations, profitability and dividends.

88.1% of REGENXBIO shares are held by institutional investors. 14.2% of REGENXBIO shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

REGENXBIO presently has a consensus target price of $23.18, suggesting a potential upside of 220.19%. Hemab Therapeutics has a consensus target price of $56.00, suggesting a potential upside of 43.37%. Given REGENXBIO's higher probable upside, equities research analysts clearly believe REGENXBIO is more favorable than Hemab Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
REGENXBIO
1 Sell rating(s)
3 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.69
Hemab Therapeutics
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.70

Hemab Therapeutics has lower revenue, but higher earnings than REGENXBIO. REGENXBIO is trading at a lower price-to-earnings ratio than Hemab Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
REGENXBIO$170.44M2.81-$193.88M-$3.21N/A
Hemab TherapeuticsN/AN/AN/A-$24.78N/A

In the previous week, REGENXBIO had 2 more articles in the media than Hemab Therapeutics. MarketBeat recorded 5 mentions for REGENXBIO and 3 mentions for Hemab Therapeutics. REGENXBIO's average media sentiment score of 0.02 beat Hemab Therapeutics' score of -0.03 indicating that REGENXBIO is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
REGENXBIO
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Hemab Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Hemab Therapeutics has a net margin of 0.00% compared to REGENXBIO's net margin of -113.85%. Hemab Therapeutics' return on equity of 0.00% beat REGENXBIO's return on equity.

Company Net Margins Return on Equity Return on Assets
REGENXBIO-113.85% -203.98% -42.54%
Hemab Therapeutics N/A N/A N/A

Summary

REGENXBIO beats Hemab Therapeutics on 8 of the 12 factors compared between the two stocks.

How does REGENXBIO compare to Recursion Pharmaceuticals?

Recursion Pharmaceuticals (NASDAQ:RXRX) and REGENXBIO (NASDAQ:RGNX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, media sentiment, profitability, risk, institutional ownership and valuation.

Recursion Pharmaceuticals has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market. Comparatively, REGENXBIO has a beta of 1.24, suggesting that its share price is 24% more volatile than the broader market.

89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. Comparatively, 88.1% of REGENXBIO shares are owned by institutional investors. 6.7% of Recursion Pharmaceuticals shares are owned by insiders. Comparatively, 14.2% of REGENXBIO shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Recursion Pharmaceuticals had 7 more articles in the media than REGENXBIO. MarketBeat recorded 12 mentions for Recursion Pharmaceuticals and 5 mentions for REGENXBIO. Recursion Pharmaceuticals' average media sentiment score of 0.07 beat REGENXBIO's score of 0.02 indicating that Recursion Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Recursion Pharmaceuticals
1 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
3 Negative mention(s)
1 Very Negative mention(s)
Neutral
REGENXBIO
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

REGENXBIO has a net margin of -113.85% compared to Recursion Pharmaceuticals' net margin of -697.15%. Recursion Pharmaceuticals' return on equity of -47.85% beat REGENXBIO's return on equity.

Company Net Margins Return on Equity Return on Assets
Recursion Pharmaceuticals-697.15% -47.85% -36.26%
REGENXBIO -113.85%-203.98%-42.54%

Recursion Pharmaceuticals presently has a consensus price target of $7.58, suggesting a potential upside of 178.68%. REGENXBIO has a consensus price target of $23.18, suggesting a potential upside of 220.19%. Given REGENXBIO's stronger consensus rating and higher probable upside, analysts plainly believe REGENXBIO is more favorable than Recursion Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Recursion Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.20
REGENXBIO
1 Sell rating(s)
3 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.69

REGENXBIO has higher revenue and earnings than Recursion Pharmaceuticals. Recursion Pharmaceuticals is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Recursion Pharmaceuticals$74.68M22.68-$644.76M-$0.90N/A
REGENXBIO$170.44M2.81-$193.88M-$3.21N/A

Summary

REGENXBIO beats Recursion Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

Get REGENXBIO News Delivered to You Automatically

Sign up to receive the latest news and ratings for RGNX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RGNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RGNX vs. The Competition

MetricREGENXBIOBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$484.02M$4.06B$7.83B$11.74B
Dividend YieldN/A3.63%2.47%4.47%
P/E Ratio-2.2626.0433.0226.92
Price / Sales2.8116.068.565.70
Price / CashN/A22.9521.0121.90
Price / Book3.234.184.463.72
Net Income-$193.88M-$24.15M$3.52B$393.10M
7 Day Performance-14.52%-7.80%-5.94%-5.76%
1 Month Performance4.47%-5.98%-4.59%-7.14%
1 Year Performance-35.64%-8.10%-1.94%-7.46%

REGENXBIO Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RGNX
REGENXBIO
2.7804 of 5 stars
$7.24
-1.1%
$23.18
+220.2%
-35.0%$484.02M$170.44MN/A371
REPL
Replimune Group
1.5377 of 5 stars
$22.26
+3.0%
$14.33
-35.6%
+124.5%$2.11BN/AN/A465
TRAX
First Tracks Biotherapeutics
3.5389 of 5 stars
$49.67
+3.7%
$72.17
+45.3%
N/A$2.09BN/AN/A104
VCYT
Veracyte
3.2327 of 5 stars
$25.79
+6.7%
$51.40
+99.3%
-38.3%$2.08B$517.15M16.66755
COAG
Hemab Therapeutics
2.4116 of 5 stars
$44.36
-9.5%
$56.00
+26.2%
N/A$2.07BN/AN/A59

Related Companies and Tools


This page (NASDAQ:RGNX) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners